Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
Top Cited Papers
- 1 August 2010
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 376 (9739), 431-439
- https://doi.org/10.1016/s0140-6736(10)60590-9
Abstract
No abstract availableKeywords
Funding Information
- Eli Lilly and Company
- Amylin Pharmaceuticals
This publication has 24 references indexed in Scilit:
- Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of TherapyDiabetes Care, 2009
- Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 DiabetesDiabetes Care, 2009
- Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority studyThe Lancet, 2008
- Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 yearsCurrent Medical Research and Opinion, 2007
- Long‐term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over‐weight metformin‐treated patients with type 2 diabetes mellitusDiabetes, Obesity and Metabolism, 2006
- Comparison of Pioglitazone and Gliclazide in Sustaining Glycemic Control Over 2 Years in Patients With Type 2 DiabetesDiabetes Care, 2005
- Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 DiabetesDiabetes Care, 2004
- Markers of Inflammation and Cardiovascular DiseaseCirculation, 2003
- Estimating Utility Values for Health States of Type 2 Diabetic Patients Using the EQ-5D (UKPDS 62)Medical Decision Making, 2002
- A sharper Bonferroni procedure for multiple tests of significanceBiometrika, 1988